Par Pharmaceutical (PRX) Tops Q1 EPS by 8c
Tweet
Share
E-mailGet Alerts PRX Hot Sheet
Price: $49.98 --0%
Financial Fact:
Operating (loss) income: 45.86M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Operating (loss) income: 45.86M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Par Pharmaceutical (NYSE: PRX) reported Q1 EPS of $0.80, $0.08 better than the analyst estimate of $0.72. Revenue for the quarter came in at $271.5 million versus the consensus estimate of $230.84 million.
For earnings history and earnings-related data on Par Pharmaceutical (PRX) click here.
For earnings history and earnings-related data on Par Pharmaceutical (PRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Lument Finance Trust (LFT) Misses Q2 EPS by 17c
- Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
